Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on oncology therapeutics, announced that its annual meeting of shareholders will be held virtually at 9 a.m. PDT on June 29, 2026. Meeting materials will be mailed following finalization and filing with the Securities and Exchange Commission.
The company also disclosed that its 2025 annual report included an audit report containing a going concern explanatory paragraph from its independent registered public accounting firm, as required under Section 610(b) of the NYSE American Company Guide. The disclosure does not reflect any change or amendment to previously filed financial statements.
Kairos Pharma, based in Los Angeles, California, utilizes structural biology to overcome drug resistance and immune suppression in cancer. Its lead candidate, ENV-105, is an antibody targeting CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types.
Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer, addressing significant unmet medical needs. As of the date of the press release, ENV-105 has not been approved as safe or effective by the U.S. Food and Drug Administration or any other comparable foreign regulator.
The going concern disclosure is important for investors as it indicates substantial doubt about the company's ability to continue as a going concern, which could affect its operations and financing prospects. However, the company continues to advance its clinical programs, including ENV-105, which targets a key mechanism of treatment resistance.
For more information, the full press release is available at https://ibn.fm/sQ0pm, and the latest news and updates relating to KAPA are available in the company’s newsroom at https://ibn.fm/KAPA.
